Varian Medical Systems, which is based in Palo Alto, California, US, recently strengthened its interventional oncology business segment by acquiring two product lines from Boston Scientific and China-based Alicon in July 2019. Both transactions will result in the addition of embolisation particles to Varian’s product offerings. 

Embolisation particles can be used as an alternative to open surgery. The use of embolisation particles is minimally invasive and blocks blood flow to a particular area of the body. This can result in the shrinkage and ablation of an aneurysm or tumour. Four main types of embolisation particles are currently used in the market, including polyvinyl alcohol (PVA) particles, microspheres, drug-eluting beads, and radioembolisation particles. 

Embolisation particles are used to treat a variety of conditions including liver cancer, renal cell carcinoma, kidney cancer, neuroendocrine tumours, arteriovenous malformations, uterine fibroids, and benign prostatic hyperplasia. The increasing prevalence of cancer, hemorrhages, and malignant hypertension are key drivers of this growing market. 

Boston Scientific agreed to sell its Oncozene and Embozene microspheres for $90m. Oncozene microspheres are used for the embolisation of arteriovenous malformations (AVMs), hypervascular tumours (HVT) and hepatoma. Embozene microspheres are used for the embolisation of prostatic arteries (PAE) for symptomatic benign prostatic hyperplasia (BPH). These assets generated over $20m for Boston Scientific in 2018. Varian does not expect this transaction to have financial implications for FY 2019. 

Alicon’s portfolio includes resorbable gel foam particles and PVA embolic beads. Alicon’s leading product is Caligel, which used in China to treat liver cancer. By acquiring Alicon, Varian will be able to use R&D programmes and networks that Alicon established in China. Varian spent $185m to purchase Alicon and the Texas-based company, Endocare. Together, these two companies had $30m in revenue, with 40% of this revenue coming from China. Similar to the purchase of the Oncozene and Embozene products, Varian does not expect the acquisition of Alicon to have financial implications in FY 2019. 

The global embolisation particles market is currently dominated by Boston Scientific and Merit Medical Systems. In 2019, Boston Scientific acquired BTG International, which manufactures microspheres, radioembolisation particles and drug-eluting beads. Therefore, despite the sale of its Oncozene and Embozene products, Boston Scientific is expected to continue to be a leader in the embolisation particle market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

View profiles in store

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Submit

UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo

Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital

Tick here to opt out of curated industry news, reports, and event updates from Medical Device Network.

Submit and download

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In 2018, GlobalData estimated the global embolisation particles market to be worth over $1.03bn, with over $380m in revenue coming from the US. GlobalData predicts a compound annual growth rate of just over 5% for the US embolisation particles market over the next decade. If Varian continues to grow its embolisation business segment, it will be on its way to becoming a major player in this market.